{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:17:43Z","timestamp":1776874663869,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dermatomyositis with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody has a distinct phenotype associated with small hand joint arthritis, mucocutaneous ulceration, palmar papules and less muscle involvement. It is also associated with increased risk of rapidly progressive interstitial lung disease (RP-ILD) and has a high mortality rate in adults. There is evidence that cases complicated with spontaneous pneumomediastinum (PNM) have an increase in mortality. While most of the evidence for this rare disease is derived from the adult literature, we report a case diagnosed in an adolescent complicated with both RP-ILD and PNM with a good outcome after aggressive immunosuppressive therapy. Our case also illustrates the potential challenges in diagnosis of this condition in the setting of non-specific clinical manifestations, the need for a high index of suspicion, and the importance of testing for myositis-specific antibodies (MSA) early to aid in diagnosis given the risk of rapid progression in these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 16-year-old Chinese female presented with fever and cough for 1 day, and finger swelling for 3 weeks. Physical examination revealed arthritis of fingers and wrists, ulcers and palmar papules over fingers, hyperpigmentation of interphalangeal joints, and rash over the neck. The diagnosis of dermatomyositis was made 1 month later with the onset of malar rash, Gottron\u2019s papules, calcinosis and myalgia. The diagnosis was supported by the presence of anti-MDA5 antibody and evidence of inflammatory myopathy on magnetic resonance imaging. In retrospect, she already had interstitial lung disease at first presentation manifested as cough and opacity on chest radiograph, which was later confirmed with chest computed tomography. She was treated according to adult guidelines with steroid and calcineurin inhibitor. Her disease was resistant to initial therapy and was complicated by RP-ILD and spontaneous PNM. Intensive immunosuppressive therapy including cyclophosphamide and rituximab were required to induce remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Recognition of distinct clinical features of anti-MDA5 antibody-positive dermatomyositis and testing for MSA is crucial in patients with skin ulceration and abnormal pulmonary findings of unknown etiology, as prompt diagnosis with early aggressive treatment and anticipation of complications could make a difference in the outcome of this disease with high mortality.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-021-00595-1","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T13:02:56Z","timestamp":1625058176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0495-1332","authenticated-orcid":false,"given":"Tsz-Wing","family":"Yeung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Ning","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Lung","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei-Chiu Niko","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"issue":"3","key":"595_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.11122","volume":"49","author":"EP Mendez","year":"2003","unstructured":"Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. NIAMS juvenile DM registry physician referral group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases registry. Arthritis Rheum. 2003;49(3):300\u20135. https:\/\/doi.org\/10.1002\/art.11122.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"595_CR2","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136. https:\/\/doi.org\/10.1002\/art.21023.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"595_CR3","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193\u2013200. https:\/\/doi.org\/10.1002\/art.24621.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"595_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626\u201336. https:\/\/doi.org\/10.1067\/mjd.2002.120621.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"595_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","volume":"54","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford). 2015;54(5):784\u201391. https:\/\/doi.org\/10.1093\/rheumatology\/keu385.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"595_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278\u201384. https:\/\/doi.org\/10.1093\/rheumatology\/ker518.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"595_CR7","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1007\/s10067-019-04729-5","volume":"38","author":"K Yamaguchi","year":"2019","unstructured":"Yamaguchi K, Yamaguchi A, Itai M, Kashiwagi C, Takehara K, Aoki S, et al. Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol. 2019;38(12):3443\u201350. https:\/\/doi.org\/10.1007\/s10067-019-04729-5.","journal-title":"Clin Rheumatol"},{"key":"595_CR8","doi-asserted-by":"publisher","unstructured":"Tansley SL, Betteridge ZE, Gunawardena H, et al. UK Juvenile Dermatomyositis Research Group. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138.\u00a0https:\/\/doi.org\/10.1186\/ar4600.","DOI":"10.1186\/ar4600"},{"issue":"10","key":"595_CR9","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/acr.21728","volume":"64","author":"H Cao","year":"2012","unstructured":"Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64(10):1602\u201310. https:\/\/doi.org\/10.1002\/acr.21728.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"595_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2010.09.016.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"595_CR11","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65(8):1307\u201315. https:\/\/doi.org\/10.1002\/acr.21992.","journal-title":"Arthritis Care Res"},{"key":"595_CR12","doi-asserted-by":"publisher","unstructured":"Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology (Oxford). 2020:keaa429.\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/keaa429.","DOI":"10.1093\/rheumatology\/keaa429"},{"issue":"4","key":"595_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/rheumatology\/ket380","volume":"53","author":"PR Mathiesen","year":"2014","unstructured":"Mathiesen PR, Buchvald F, Nielsen KG, Herlin T, Friis T, Nielsen S. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. Rheumatology (Oxford). 2014;53(4):644\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/ket380.","journal-title":"Rheumatology (Oxford)"},{"key":"595_CR14","unstructured":"Sato S, Kobayashi N, Yamazaki K, Suzuki Y. Clinical utility of anti-CADM-140\/melanoma differentiation-associated gene 5 autoantibody titres in patients with juvenile dermatomyositis and rapidly progressive interstitial lung disease [Abstract 292]. In: American College of Rheumatology 76th Annual Meeting; November 2012; S128."},{"issue":"7","key":"595_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137. https:\/\/doi.org\/10.1056\/NEJM197502132920706.","journal-title":"N Engl J Med"},{"issue":"12","key":"595_CR16","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, et al. European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955\u201364. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468.","journal-title":"Ann Rheum Dis"},{"key":"595_CR17","doi-asserted-by":"publisher","unstructured":"Xu A, Ye Y, Fu Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford). 2020:keaa786.\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/keaa786.","DOI":"10.1093\/rheumatology\/keaa786"},{"issue":"7","key":"595_CR18","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","volume":"78","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG. Mammen AL; childhood myositis heterogeneity collaborative study group. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019;78(7):988\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2018-215004.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"595_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/acr.20071","volume":"62","author":"AM Huber","year":"2010","unstructured":"Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's arthritis and rheumatology research Alliance consensus conference. Arthritis Care Res (Hoboken). 2010;62(2):219\u201325. https:\/\/doi.org\/10.1002\/acr.20071.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"2","key":"595_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209247.","journal-title":"Ann Rheum Dis"},{"key":"595_CR21","doi-asserted-by":"publisher","unstructured":"Kawasumi H, Gono T, Kawaguchi Y, Yamanaka H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):9\u201317. https:\/\/doi.org\/10.4137\/ccrpm.s23313.","DOI":"10.4137\/ccrpm.s23313"},{"issue":"4","key":"595_CR22","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E, et al. MEDRA5 (Spanish MDA5 register) group (listed contributors at the end of the article). Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50(4):776\u201390. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.03.007.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"595_CR23","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","volume":"37","author":"H So","year":"2018","unstructured":"So H, Wong VTL, Lao VWN, Pang HT, Yip RML. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol. 2018;37(7):1983\u20139. https:\/\/doi.org\/10.1007\/s10067-018-4122-2.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"595_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/ar3531","volume":"13","author":"EC Baechler","year":"2011","unstructured":"Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther. 2011;13(6):249. https:\/\/doi.org\/10.1186\/ar3531.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"595_CR25","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"Ladislau L, Su\u00e1rez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609\u201321. https:\/\/doi.org\/10.1093\/brain\/awy105.","journal-title":"Brain."},{"key":"595_CR26","doi-asserted-by":"publisher","unstructured":"Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59.\u00a0https:\/\/doi.org\/10.1093\/brain\/awz293.","DOI":"10.1093\/brain\/awz293"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00595-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T13:06:38Z","timestamp":1625058398000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00595-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00595-1","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Formal written consent for publication was obtained from the patient and her mother and is available on request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Formal written consent for publication was obtained from the patient and her mother and is available on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}